Bacteria have no pre-existing defenses against this target
En un momento en que la resistencia bacteriana amenaza con revertir décadas de progreso médico, investigadores de la Universidad McMaster han descubierto la manikomicina, un antibiótico que ataca a los microbios por un flanco que la medicina nunca había explorado. El compuesto bloquea la salida del ribosoma bacteriano —la maquinaria que fabrica proteínas—, un mecanismo tan inédito que las bacterias aún no han tenido tiempo evolutivo para defenderse de él. Este hallazgo, el cuarto de su tipo en el laboratorio del profesor Gerry Wright en poco más de un año, sugiere que la naturaleza aún guarda secretos capaces de renovar nuestra capacidad de curar.
- La resistencia a los antibióticos avanza más rápido que el desarrollo de nuevos fármacos, dejando a médicos sin opciones frente a patógenos como E. coli, Salmonella y Klebsiella.
- La manikomicina irrumpe con una lógica radicalmente distinta: en lugar de atacar los mismos puntos del ribosoma que todos los antibióticos actuales, bloquea la salida de la cadena de producción proteica, paralizando a la bacteria desde adentro.
- Porque ningún antibiótico ha presionado jamás ese punto del ribosoma, las bacterias carecen de mecanismos de resistencia preexistentes —una ventana de vulnerabilidad que la ciencia nunca había abierto.
- El equipo ya superó dos obstáculos críticos: la manikomicina no es tóxica para células humanas y funciona en modelos de infección controlados.
- Ahora los investigadores optimizan la persistencia del fármaco en el organismo y evalúan 60 derivados para determinar cuál tiene más posibilidades de llegar a ensayos clínicos.
Investigadores de la Universidad McMaster, en Canadá, han identificado un antibiótico llamado manikomicina que mata bacterias resistentes a los fármacos atacando una vulnerabilidad que ningún medicamento había tocado antes. Publicado en Nature y liderado por el profesor Gerry Wright, el hallazgo muestra eficacia temprana contra Salmonella, E. coli y Klebsiella, organismos que se han vuelto cada vez más difíciles de tratar.
Lo que distingue a la manikomicina es su mecanismo. Todos los antibióticos actuales —azitromicina, tetraciclina y sus parientes— atacan los mismos puntos del ribosoma bacteriano. La manikomicina, en cambio, bloquea la salida de ese ribosoma: la zona por donde deben escapar las proteínas recién fabricadas para que la producción continúe. Wright lo describe como atascar la línea de ensamblaje justo en la salida, lo que detiene toda la fábrica. Sin proteínas, la bacteria no puede sobrevivir. Y como ese punto nunca ha sido atacado en la historia de la medicina, las bacterias no tienen defensas preparadas.
El descubrimiento nació de revisar lo que se creía agotado. Streptomyces rimosus, la bacteria del suelo que hace más de 75 años produjo la oxitetraciclina, fue considerada durante décadas una fuente exhausta. El equipo de Wright aplicó una técnica de fraccionamiento que filtra los compuestos abundantes y conocidos para aislar moléculas raras que habían pasado desapercibidas. La investigadora Manpreet Kaur, autora principal del estudio, señala que incluso bacterias bien estudiadas pueden esconder compuestos valiosos si se analizan con mayor cuidado.
La manikomicina ya superó dos hitos esenciales: no es tóxica para células humanas y funciona en modelos de infección de laboratorio. El equipo trabaja ahora en mejorar cuánto tiempo permanece activa en el organismo y evalúa 60 derivados para encontrar el candidato más sólido de cara a ensayos clínicos. Es el cuarto antibiótico candidato que emerge del laboratorio de Wright en poco más de un año, una cadencia que sugiere que este enfoque de descubrimiento podría transformar la forma en que la medicina enfrenta la resistencia bacteriana.
Researchers at McMaster University in Canada have identified a new antibiotic that kills some of the world's most dangerous drug-resistant bacteria by exploiting a vulnerability that has never been targeted before. The compound, called manikomicin, was discovered by a team led by professor Gerry Wright and published in Nature. It shows early promise against priority pathogens including Salmonella, E. coli, and Klebsiella—organisms that have become increasingly difficult to treat as they develop resistance to existing drugs.
What makes manikomicin fundamentally different is how it works. Rather than attacking the same weak points in bacterial ribosomes that current antibiotics target, it blocks the exit site of the ribosome—the cellular machinery responsible for manufacturing proteins. No antibiotic currently prescribed in clinics operates this way. Wright, who directs the Michael G. DeGroote Institute for Infectious Disease Research, emphasizes that azithromycin, tetracycline, and every other antibiotic in use today leave this particular target untouched. The discovery is significant not just because a new drug candidate exists, but because it reveals an entirely new vulnerability that future antibiotics could exploit.
The reason this matters becomes clear when you understand how bacterial resistance develops. Most antibiotics in use today attack the same handful of ribosomal targets, so bacteria have evolved multiple defense strategies against these conventional attacks over decades of exposure. The exit site, however, has never been under selective pressure in the history of medicine. Bacteria have no pre-existing resistance mechanisms to manikomicin because no one has ever attacked them there before. Wright uses an assembly line metaphor to explain the mechanism: the ribosome works like a factory where finished components must be removed before the next piece can move forward. Manikomicin jams the exit, causing the entire assembly process to stall and eventually halt completely. Without the ability to manufacture proteins, bacteria cannot survive.
This discovery represents the fourth new antibiotic candidate to emerge from Wright's laboratory in just over a year, suggesting a fundamentally new and promising approach to drug discovery at a moment when antibiotic resistance poses a growing global threat. The work builds on research that stretches back more than 75 years, when scientists first discovered that a soil bacterium called Streptomyces rimosus produced oxytetracycline—a powerful drug that helped usher medicine into the antibiotic era. For decades, S. rimosus and related bacteria were considered exhausted sources, picked clean of useful compounds. Wright's team has proven this assumption wrong.
The breakthrough came through a sophisticated laboratory technique called fractionation. By filtering out the abundant compounds like oxytetracycline from the chemical mixtures produced by S. rimosus, researchers isolated rare molecules that had gone unnoticed for years. Manpreet Kaur, a postdoctoral researcher in Wright's lab and lead author of the study, notes that this approach opens new pathways for antibiotic discovery. Even well-studied bacteria like Streptomyces may still harbor undiscovered compounds waiting to be isolated through more careful analysis.
The team has already cleared important early hurdles. Manikomicin has proven non-toxic to human cells and performs well in controlled laboratory infection models—two critical milestones in early-stage drug development. Researchers are now focused on optimizing how long the drug remains active in the body, a property known as drug persistence. They have synthesized 60 different derivatives of manikomicin and are working to identify which version shows the most promise for advancing into clinical trials. The path from laboratory discovery to approved medication typically takes years and requires navigating regulatory approval, but Wright's team has demonstrated both the scientific foundation and the momentum to pursue this new class of treatment.
Citações Notáveis
No antibiotic currently prescribed in clinics does what manikomicin does. We have not only found a new drug candidate, but identified a new target in bacteria that could be exploited by other new drugs.— Gerry Wright, McMaster University
Bacteria have no pre-existing resistance mechanisms to manikomicin because no one has ever attacked them at this site before.— Gerry Wright, McMaster University
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that manikomicin attacks a part of the ribosome that no other antibiotic targets?
Because bacteria have spent decades—maybe centuries—developing defenses against the same few ribosomal targets. They've had no reason to develop defenses against the exit site because nothing has ever attacked it. It's like a fortress with guards everywhere except one gate.
So even if bacteria develop some resistance to manikomicin eventually, we'd have a head start?
Exactly. We're not starting from zero resistance like we do with new drugs that hit the old targets. And more importantly, we've identified a completely new place to attack. That means the next drug Wright's team discovers could hit a different part of the ribosome entirely.
How did they find this if bacteria like Streptomyces have been studied for 75 years?
They used a technique called fractionation to filter out all the abundant, well-known compounds. What was left were rare molecules that had been hiding in plain sight. It's like finally looking carefully at something everyone assumed was already fully explored.
What's the biggest hurdle now?
Getting the drug to stay active long enough in the human body. They've made 60 different versions trying to solve that problem. Once they optimize that, they can move toward actual human trials.
Does this solve the antibiotic resistance crisis?
No single drug solves it. But this opens a door. If Wright's lab can find more drugs that attack different ribosomal sites, we suddenly have multiple new weapons instead of just variations on the old ones. That's how you stay ahead of resistance.